Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) fragility in FANCM−/− patient-derived immortalized
fibroblasts treated with diepoxybutane or olaparib. We
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа, inflammation,
fibroblast proliferation and the production of excess collagen. Therefore, in the treatment of NF
Parfenova, L.V.,
Galimshina, Z.R.,
Gil'fanova, G.U.,
Alibaeva, E.I.,
Danilko, K.V.,
Pashkova, T.M.,
Kartashova, O.L.,
Farrakhov, R.G.,
Mukaeva, V.R.,
Parfenov, E.V.,
Nagumothu, R.,
Valiev, R.Z. (2022) the viability of
fibroblasts (by 20–40%), osteoblast-like cells MG-63 (by 30–60%), and mesenchymal stem cells